Several systemic factors have been shown to contribute to the acceleration of large vessel atheroma. Correction of these factors leads to a reduction in the progression of plaque formation and associated arterial wall thickness. Atheroma remains, however, a focal disease, developing at characteristic sites within the arterial tree. These sites are typically at areas of vessel branching or marked curvature, and correspond to regions of high tensile stress and low sheer stress, leading to the hypothesis that local haemodynamic factors and vessel wall mechanics potentiate the focal development of atheroma.
Introduction
Atherosclerosis continues to be a major cause of morbidity and mortality worldwide. Our understanding of the underlying atherosclerotic process remains limited. Initial clinical manifestations are often associated with advanced disease.
The advent of high-resolution ultrasound has allowed accurate and reproducible measurement of the intima-media of the far wall and lumen diameter (LD) of large arteries. 1 Studies have shown that increases in intima-media thickness (IMT) of the common carotid artery occur with age, and are associated with a number of cardio-vascular risk factors. 2, 3 Carotid IMT has been shown to be both predictive of and an independent risk factor for cardiovascular morbidity and mortality. 4, 5 These data suggest that measurement of carotid IMT offers a surrogate for early atherosclerosis.
A previous study has demonstrated that carotid IMT regresses with treatment of hypertension with calcium channel blocker (CCB) or angiotensin-converting enzyme (ACE) inhibitorbased therapy. The magnitude of IMT regression and the pattern of remodelling differed between these agents, despite similar blood pressure (BP) reductions. 6 These changes may be a consequence of different biochemical effects of the two drugs on the cellular components of the vessel wall or different effects on local haemodynamic forces, an observation that may parallel the differential effects of antihypertensive therapies on cardiac structure in man. 7 There is accumulating evidence that local haemodynamic forces influence growth and remodelling of blood vessels. 8, 9 Much interest in the association of local haemodynamics and atherosclerosis has been stimulated by observations that atherosclerotic plaques are focally distributed. 10 Plaque typically occurs at vessel bifurcations or sites of curvature, where shear stress may be low, and tensile stress high. 11 Work in this field has been limited by a lack of accurate determination of local haemodynamics, with local haemodynamic parameters often being derived from equations based on 2D structure and flow estimates. 12 With the development of computational fluid dynamic (CFD) techniques, modelling of local haemodynamics in a three-dimensional environment has become possible. This technique involves the numerical solution of the set of partial differential equations, (the Navier Stokes equations) that describe flow. The solution of the Navier Stokes equations requires boundary conditions which, with the equations, govern the associated physical behaviour of the system. These boundary conditions comprise the three-dimensional geometry of the vessel and details of the flow entering or leaving the vessel. The geometry provides a 'mesh' within which the equations may be solved, and flow and pressure data within the vessel provide limits to the iterative equation solving processes.Whilst MRI data have been successfully applied to this technique, 13 we have shown that carotid artery data obtained from a custom three-dimensional ultrasound system can also be successfully applied to these CFD codes, 14 providing a novel, convenient and non-invasive technique for local haemodynamic estimations.
CACHET seeks to examine changes in carotid structure and haemodynamics in relation to two antihypertensives with different mechanisms of action.The application of CFD techniques to data acquired during this study will enable examination of the relationship of arterial structural changes to local haemodynamics.
Study objectives
Primary objective G To compare and contrast the effects of two antihypertensive regimens, one based on an angiotensin receptor blocker (ARB) and the other on a β-receptor blocker, on common carotid IMT in poorly controlled or untreated hypertensives.
Secondary objective
G To compare and contrast the effects of the two regimens on carotid bulb IMT. G To compare and contrast the effects of the two regimens on left ventricular mass index (LVMI).
Tertiary objective G To explore the relationship between local IMT and local haemodynamic parameters as predicted by CFD applied to ultrasound data. G To relate any differences in IMT regression between the antihypertensive regimens to differences in local haemodynamics.
Patient selection Subjects
All patients for this study have been recruited from the Peart-Rose clinic, the specialist hypertension clinic at St Mary's Hospital, or directly from their local general practitioners.
Recruitment methods
Patients referred to the Peart-Rose clinic thought eligible for the study were approached during their routine clinic visits. In addition, local general practitioners were independently approached with information of the studies to be undertaken. They provided names of their patients considered eligible. Questionnaires were sent to these patients informing them of the clinical study. Those indicating interest were then contacted via telephone to identify eligibility. Those thought eligible were then offered appointments at the Peart-Rose clinic, where they were assessed and informed of the studies in detail. Each patient recruited gave signed consent. The general practitioners were kept fully informed.
In total, 490 patients were contacted, 440 of whom underwent telephone screening following return of their questionnaires. Of the 440 contact-ed by telephone, 190 patients were either ineligible based on a brief history, or declined entry into the study. The remaining 300 patients were invited to undergo a screening echocardiogram to determine their LVMI, and a carotid ultrasound to ensure that the carotid IMT was evaluable. Ninetyfive patients were selected from this group on the basis of these investigations, although after further screening, only 88 patients were found suitable for randomisation into the study.
Inclusion criteria
Men and women, aged between 35 and 80 years, were eligible if they were hypertensive by study definitions: all subjects, whether currently on treatment or untreated, had clinic systolic blood pressures (SBP) of >160 mmHg and/or clinic diastolic blood pressures (DBP) of >95 mmHg. Patients were considered 'untreated' if they had never had antihypertensive treatment, or less than three weeks of antihypertensive treatment in last two years.
To help identify a population likely to have vascular adaptation in response to poorly-controlled BP, a minimum LVMI of >100 g/m 2 in males and >85 g/m 2 in females (PENN criteria) was specified.
Only patients in whom the right common carotid artery was easily evaluable by ultrasound were recruited.
Exclusion criteria
Patients were excluded if they had evidence of major organ dysfunction, identified clinically or with blood sampling, or a recent cardiovascular event. Patients with contraindications to the study drugs, pregnancy, diabetes or dyslipidaemia were also excluded.
Study design
Ethical approval for the study was obtained from the local Ethics Committee at St Mary's Hospital. All participants gave informed consent before entering the study.
This was a double-blind, parallel-group study assessing two antihypertensive regimens.The study duration was 56 weeks: two weeks withdrawing from treatment (where relevant), two weeks of placebo run in, and 52 weeks of active treatment.
Each patient underwent a minimum of eight visits, with extra visits scheduled at the investigator's discretion to ensure target BP was attained. At each visit, clinic BP was monitored in the morning, prior to that day's dose.
Target BP was defined as a morning pre-dose clinic BP of <140/90 mmHg.
At the initial screening visit (Visit one) patients underwent BP monitoring, a screening echocardiogram and carotid ultrasound to ensure eligibility for the study. A full medical history was taken and medical examination performed. In addition, ECG, chest X-ray and screening baseline blood tests were also performed.Those found eligible for the study were carefully withdrawn from their current drug regimen.
Patients returned two weeks later, for dispensing of placebo (Visit two). During this visit, there was an option to 'fast-track' patients starting placebo onto active treatment in as little as two days, depending on the level of BP and at the investigator's discretion.
Patients returned after two weeks of placebo treatment for drug randomisation. During this visit (Visit three), 24-hour ambulatory BP was performed, as well as full endpoint assessment. This included full Duplex ultrasound examination of the right carotid artery, echocardiogram and ECG.
Once randomised onto active treatment, patients were reassessed three weeks later, or sooner if considered 'fast-track' (Visit four). Blood samples were taken to ensure plasma creatinine remained stable after the initiation of the drug.
Visit five was performed 11 weeks later. Visit six involved repeat endpoint assessment 12 weeks later (30 weeks into the study and 26 weeks after active treatment had been commenced).
Visit seven occurred 13 weeks after visit six. Visit eight, the final visit, was performed at week 56 of the study, providing endpoint data after 52 weeks of active treatment. Twenty-four-hour ambulatory BP was also performed at this visit whilst subjects were taking study medication.
Study medication
Antihypertensive treatment was initiated by random, double-blinded allocation to either atenolol, 50 mg once-daily (OD), or candesartan cilexetil, 8 mg OD (Dose B). If target BP was not achieved, then these doses were increased to the maximal doses of atenolol (100 mg OD) or candesartan (16 mg OD) (Dose C). If target BP was still not achieved, then a common treatment sequence of second-, third-and fourth-line therapy was added. This was defined as hydrochlorothiazide (12.5-25 mg OD), felodipine (5-10 mg OD) and doxazosin (4-16 mg OD).
Randomisation
Eligible patients were randomised onto active treatment using minimisation procedures based on sex, age, ethnicity and severity of hypertension, as indicated by LVH defined by PENN Criteria.
Methods

Blood pressure measurements
All BP measurements were made using a fully automated device (Omron HEM-705-CP). Measurements were taken from the right arm unless clinically contraindicated.The SBP/DBP and pulse was measured at each study visit after the patient has rested in a quiet room for a minimum of 5 minutes. Five consecutive sitting measurements were made with at least a 1minute interval between readings. The two extreme values (highest and lowest) were discarded, and the mean BP calculated from the remaining three values.
In cases of the Omron failing to record a BP, the BP measurement was made with a manual sphygmomanometer.
Twenty-four-hour ambulatory blood pressure monitoring
Twenty-four-hour ambulatory BP and heart rate were evaluated using a Spacelabs 90207 device. Measure-ments were made at half-hourly intervals during the day and hourly intervals at night.
Common carotid and bulb intima-media measurement
Subjects were examined in the supine position, with the neck extended and rotated 45°towards the contra-lateral side. The right common carotid artery was scanned using a 7.5 MHz ultrasound transducer (12-5 scanhead probe on an HDI 5000 ultrasound scanner, ATL, Washington). Common carotid images were obtained from the anterior, antero-lateral and posterior planes.Images were recorded over the duration of six cardiac cycles and then transferred to a Pentium class PC for subsequent analysis. For the determination of bulb and common carotid IMT, images of the bulb and distal common carotid focused on the far wall were used. The bulb dilation served as a landmark indicating the border between distal vessel and the bifurcation area. All images were recorded with concomitant ECG traces so that gating was possible.
Using HDI Lab, (Software version 1.86, ATL, Washington) the image loops downloaded were viewed on PC 'off-line'.
An image was selected from each of the three planes during diastole, defined by the peak of the Rwave. Using a semi-automated IMT analysis package (AMS V6 Chalmers University, Götenburg, Sweden), an average common carotid IMT and lumen diameter was measured over a 5-15 mm segment for each projection from the right carotid system. Bulb IMT measurements were made over a 5 mm segment directly distal to the bulb dilation, again in three projections.
The mean value of all three measures was used as an average bulb and common carotid IMT for each subject.
Common carotid Doppler measurement
The right common carotid artery of each subject was examined in the supine position, with the neck extended and rotated to 45°to the contra-lateral side.
Pulse wave Doppler ultrasound was performed at 6 MHz using a 12/6 MHz linear array ultrasound transducer (12-5 scanhead probe on an HDI 5000 ultrasound scanner, ATL,Washington).
Doppler recordings were made in the centre of the vessel using a sample volume of 1.5 mm 2 at the most distal point possible in internal and external carotid arteries, and at a distance of 2 cm proximal to the bulb in the common carotid artery. The angle between the vessel and the Doppler beam was maintained as close as possible to 60°.
The pulsed Doppler velocity waveform was acquired continuously for ten cardiac cycles at a frequency of 100 Hz with a simultaneous ECG trace. These data were transferred to a Pentium class PC for subsequent analysis using the HDILab software.
Applanation tonometry
Subjects were examined in the supine position with the neck extended. The tonometer (model SPT-301; Millar Instruments, Inc., Texas, USA) was applied to right common carotid artery to achieve good applanation.The signal generated was amplified (TCB-500 pre-amplifier, Millar Instruments Inc.), the output converted to a digital signal via an analogue to digital board within a Pentium class PC and recorded using commercially available software (Dasylab V4.7, Dasytec, Moenchengladbach, Germany). A simultaneous single lead ECG trace, via an external ECG monitor, was also digitised and recorded via Dasylab software.Care was taken to achieve optimal pressure waveforms. Approximately 20 continuous waveforms were obtained and stored per session.
LVMI measurement
Patients were examined using a standard ultrasound examination protocol. 15 Images were obtained using a 4-2 MHz ultrasound transducer (HDI 5000, ATL, USA). Left ventricular (LV) septal wall thickness, posterior wall thickness and cavity size were measured from the LV short axis view, using 2D guided Mmode. Particular attention was paid to obtaining a precise cross-sectional 'on-axis' image of the LV at the papillary muscle tip level. Measurement of LV septum, posterior wall and cavity dimensions were made at end diastole, using the Penn convention, 16 using the images downloading via HDILab software.
LV mass was calculated from Penn measurements, using the cubed formula with an appropriate validation factor. 16 The resulting LV mass was adjusted for body size by dividing by body surface area (BSA), obtained from an algorithm based on the subjects height and weight, to give the LV mass index (LVMI) in g/m 2 . 17
3D ultrasound
Anatomically realistic arterial geometry was determined using the 3D ultrasound imaging system developed in our laboratory and illustrated in Figure   1 . The system makes use of an electromagnetic tracking device (the pcBIRD, Ascension Technologies Corp., Vermont, USA) to track the motion of a conventional (i.e. 2D) ultrasound scan probe in space. The tracking device comprises an electromagnetic transmitter, fixed to the side of the examination couch, and a small sensor mounted on the ultrasound scan probe.An electronic controller is installed in a PC and enables the position and orientation of the scan probe to be measured during an ultrasound scan with minimal interference to the normal freehand ultrasound scanning technique.
During a 3D ultrasound scan,the scan probe was swept slowly along the neck. As the probe was swept, a series of transverse 2D ultrasound images were captured at regular intervals. Simultaneously, their relative 3D positions and orientations were recorded using the tracking device. Using these data, the 3D volume interrogated during the ultrasound scan was reconstructed. In order to reduce artefacts in the 3D reconstruction due to arterial wall motion, image acquisition was ECG-gated: in particular, each image was captured following a preset delay relative to the peak of the QRS complex. Captured ultrasound images, which represent cross-sectional slices through the scanned artery, were stored in a digital format on the scanner and downloaded to the PC at the end of a scan for off-line analysis. The 3D ultrasound system was designed specifically for vascular applications and takes advantage of the digital image capture facilities of the ATL HDI5000 ultrasound scanner (ATL-Philips Ltd, Bothell, USA). High-resolution ultrasound images were acquired using the L12-5 linear array transducer (5-12 MHz) and power Doppler mode; each image comprised a B-mode image together with a colour overlay indicating blood flow in the lumen. Full details of the operation and validation of the 3D ultrasound system have been previously reported. [18] [19] [20] The carotid artery bifurcation was reconstructed using a surface modelling approach. Initially, wall contours were defined by hand on each captured ultrasound image slice with the aid of a customwritten software tool. 18 Each contour was defined by a smooth, planar curve and represented a crosssection through the vessel wall (see Figure 2A ). For most images, the time taken to define contours was significantly decreased by taking advantage of the elliptical shape of the vessel cross-section. A fast ellipse-fitting algorithm, which required only six points or more to be specified on the vessel wall, was applied where vessel cross-sections were approximately elliptical. Alternatively, a cubic spline curve was used to represent the vessel wall in regions such as the bifurcation, where an elliptical approximation is not deemed valid.
Once a set of cross-sectional contours had been defined, reconstruction artefacts were reduced by realigning misregistered contours. Such misregistration may occur, for example, due to vessel motion. The process of contour realignment involved fitting a smoothing spline curve to the centroids of the contours and then shifting each contour within its original scan plane so that its centroid coincides with the fitted curve. The vessel surface was modelled by fitting longitudinal spline curves to the vertices of the realigned contours.Thus, the 3D vessel geometry was completely defined by a set of smooth curves, as shown in Figures 2B and 2C .The representation has the advantage of being efficient in terms of the amount of memory required to store the surface. It is also suitable for use with fluid modelling techniques outlined below.
Computational fluid dynamic (CFD) modelling
Surface splines obtained from 3D ultrasound data were used as input for a commercial computer aided design package (ICEM-DDN) to produce the input file for a grid generator (ICEM Hexa) (ICEM CFD engineering, Warwick CV34, UK). This semiautomated Hexa grid tool was used to generate a fully structured, multi-block hexahedral cell grid for use with the designated solver CFX-4.4 (AEA Technology, Didcot, Oxfordshire OX11, UK). CFX-4.4 provides a numerical solution to the complex partial differential equations that describe flow, the Navier-Stokes equations (Figure 3 ).
Data obtained from Doppler ultrasound, together with tonometry data, were used to establish the initial and boundary conditions, and to act as limits for iterative processes used to solve these equations. 21 Parameters of flow derived included: G Shear stress, oscillatory shear stress, tensile wall stress, particle residence time and flow separation.
Statistical methods
Sample size
The predicted increase in common carotid IMT over a year is 0.006 mm (+0.05 mm SD). 22 Based on previous studies the anticipated difference in IMT from baseline with treatment of hypertension was assumed to be 0.04-0.10 mm, with an assumed SD of change in IMT of 0.05 mm. 6, 23 A difference between treatment regimen of 0.01-0.05 mm was considered to be of clinical relevance. Hence, using the two-sided alternative null hypothesis with α=0.05, 40 patients per treatment arm allows: -A between treatment difference in IMT regression of 0.031 mm with 80% power. -A between treatment difference in IMT regression of 0.036 mm with 90% power.
To ensure a balanced number of patients in each treatment group, an independent biostatistician reviewed the randomisation with the treatment codes once 40 patients had been recruited.
Statistical analyses
All data will be analysed according to the intention to treat principle.
Comparison of regression of distal common carotid IMT consequent to BP-lowering by candesartan and by atenolol will be performed using ANCOVA with change in SBP as a covariate.
Similar ANCOVA with change in SBP as a covariate will be performed to analyse the secondary objectives.
Baseline data
Recruitment for CACHET is now complete.
Eighty-eight patients were randomised into the study from the potential 95 initially identified on the basis of initial BP and LVMI measurements. Of the seven found unsuitable, three had a dyslipidaemia, and four were normotensive, but with significant 'white coat' effect as demonstrated on a 24-hour ABPM.
The 88 patients randomised comprised: G 35 Caucasian males G 23 Caucasian females G 7 Afro-caribbean males G 11 Afro-caribbean females G 10 Asian/mixed race males G 2 Asian/mixed race females Although the majority of subjects (n=56) were on treatment when randomised into the study, 32 were drug naïve on entry. Of those on treatment, 31 were on a single antihypertensive agent, 21 on two agents and four on three agents (see Table 1 ).
The mean SBP of the previously treated group, prior to randomisation, was 165 mmHg (SD+15), with mean DBP of 101 mmHg (SD+8). The mean SBP of the untreated group prior to randomisation was 161 mmHg (SD+14), with mean DBP of 103 mmHg (SD+6).
Thirty-one patients had left ventricular hypertrophy as defined by LVMI >134 g/m 2 in males, and 110 g/m 2 in females (PENN criteria).
The baseline characteristics of the group are summarised in Table 2 .
Discussion
CACHET ended recruitment in March 2001 and is now closed.This study will provide us with important data comparing and contrasting the differing effects of a β-receptor blocker and an ARB on carotid IMT and LVMI regression after a year of treatment.
A previous study 6 demonstrated markedly different IMT regression between a CCB-based and an ACE-I based antihypertensive regimen, despite similar BP reductions.Although IMT regressed significantly from baseline with both treatment regimens, there was greater regression of the common carotid IMT in the CCB-based regimen than in the ACE-I regimen.There was, however, a preservation of wall mass in both groups when compared to the baseline study data, suggesting that vascular remodelling had occurred with both regimens. Interestingly, a recent review indicates much less regression of structural changes in small arteries with β-receptor blockers than with other classes of antihypertensives. 24 It will be of interest to Table 1 Summary of drug usage prior to study entry.
Summary of drug usage prior to study Numbers
Treated/untreated 56/32
On a single agent 21
On two agents 26
On three or more agents 4
On β-receptor blocker alone or in combination 26
On ACE-I alone or in combination 16
On β-receptor blocker and diuretic 13 examine whether this finding also applies to large arteries subject to atherosclerotic disease. Although carotid artery vascular remodelling is yet to show prognostic benefit, it will perhaps be tempting to interpret the findings of the CACHET study in the light of the results of the LIFE study. 25 The acquisition of 3D ultrasound geometry, pressure data and Doppler flow data at baseline, midway and at the end of the study provides us with a unique and novel opportunity to examine the effects of treatment on haemodynamics and the relationship between changes in haemodynamics and wall remodelling. CFD provides comprehensive haemodynamic information far beyond that possible with flow predictions based on 2D models. CFD methods are able to generate complete 3D information on flow velocity, intimal shear stress, circumferential wall stress, particle residence time and tracking. 26 These data should provide a valuable insight into the determinants of vascular remodelling in a clinical setting, and will aid our understanding of the atherosclerosis process and the impact of drugs on this process.
